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Abstract
Background—Medication nonadherence rates are high. The factors predicting nonadherence in heart failure
remain unclear.
Methods and Results—A sample of 202 adults with heart failure was enrolled from the northeastern United
States and followed for 6 months. Specific aims were to describe the types of objectively measured medication
adherence (eg, taking, timing, dosing, drug holidays) and to identify contributors to nonadherence 6 months
after enrollment. Latent growth mixture modeling was used to identify distinct trajectories of adherence.
Indicators of the 5 World Health Organization dimensions of adherence (socioeconomic, condition, therapy,
patient, and healthcare system) were tested to identify contributors to nonadherence. Two distinct trajectories
were identified and labeled persistent adherence (77.8%) and steep decline (22.3%). Three contributors to
the steep decline in adherence were identified. Participants with lapses in attention (adjusted OR, 2.65;
P=0.023), those with excessive daytime sleepiness (OR, 2.51; P=0.037), and those with ≥2 medication
dosings per day (OR, 2.59; P=0.016) were more likely to have a steep decline in adherence over time than to
have persistent adherence.
Conclusions—Two distinct patterns of adherence were identified. Three potentially modifiable contributors
to nonadherence have been identified.
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Abstract
Background—Medication nonadherence rates are high. The factors predicting nonadherence in
heart failure (HF) remain unclear.
Methods and Results—A sample of 202 adults with HF was enrolled from the Northeastern
U.S. and followed for 6 months. Specific aims were to describe the types of objectively measured
medication nonadherence (e.g. taking, timing, dosing, drug holidays) and to identify contributors
to nonadherence 6 months after enrollment. Latent growth mixture modeling (GMM) was used to
identify distinct trajectories of adherence. Indicators of the five World Health Organization
(WHO) dimensions of adherence (socioeconomic, condition, therapy, patient, and health care
system) were tested to identify contributors to nonadherence. Two distinct trajectories were
identified and labeled persistent adherence (77.8%) and steep decline (22.3%). Three contributors
to the steep decline in adherence were identified. Participants with lapses in attention (adjusted
odds ratio (OR) = 2.65, p=0.023), those with excessive daytime sleepiness (OR = 2.51, p=0.037),
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and those with two or more medication dosings per day (OR = 2.59, p=0.016) were more likely to
have a steep decline in adherence over time than to have persistent adherence.
Conclusions—Two distinct patterns of adherence were identified. Three potentially modifiable
contributors to nonadherence have been identified.
Keywords
heart failure; medication adherence; patient compliance; self-care; sleep; World Health
Organization
It is estimated that 20–50% of chronically ill patients in general,1 and 40–60% of adults with
heart failure (HF) in particular,2 are nonadherent with medications. Number of
hospitalizations, in-patient days, emergency department visits, healthcare costs, and
mortality are higher in HF patients who do not take their medications as prescribed.3–5
Medication adherence is defined as the extent to which the patient’s medication-taking
behavior corresponds with an agreed upon medication regimen from a health care provider.6
Adherence requires both behavioral execution and persistence in medication taking.7 Four
components are involved in the assessment of medication adherence: 1) taking adherence
(taking the prescribed medicines each day), 2) dosing adherence (taking the correct number
of doses each day); 3) timing adherence (taking doses within ± 2 hr of the time prescribed);
and 4) avoiding drug holidays (e.g. more than 48 hours between doses).
A wide variety of factors have been identified as contributors to medication nonadherence.
The WHO groups factors influencing adherence into five dimensions.8 The socioeconomic
dimension includes race and income. Condition-related factors include symptoms and
depression. The therapy-related dimension includes treatment complexity. Patient-related
factors are both physical (e.g. cognitive impairment) and psychological/behavioral (e.g.
health perceptions). Finally, health care system-related factors include the high costs of
drugs and specialty services.
Although numerous studies of medication nonadherence in adults with HF have been
conducted, several gaps remain in our knowledge.1, 2 Most studies of medication adherence
in HF are cross-sectional in design and sample sizes are often small. Many different tools
are used in measuring adherence, which makes it difficult to compare across studies. Self-
report is the most commonly used method of adherence measurement; we located only 4
studies using electronic monitoring in HF patients.5, 9–11 And, bivariate analyses testing
single hypotheses have failed to provide an adequate picture of the manner in which factors
interact to contribute to medication nonadherence in HF patients.12, 13
We previously demonstrated that adults with HF and excessive daytime sleepiness (EDS)
self-reported more problems adhering to their medication regimen than those without EDS.
Lapses in attention interfered with the vigilance needed to remember their medications,
leading to reports of nonadherence.14 In this study we sought to build on these results and
fill some of the knowledge gaps with objective data on medication nonadherence collected
over a 6 month period using electronic monitoring technology manufactured by AARDEX
(www.aardex.com), the Medication Event Monitoring System (MEMS). The specific aims
of this study were to identify and describe common and distinct trajectories of nonadherence
(e.g. taking, timing, dosing, drug holidays) during a prospective study of adults with HF and
to identify contributors to medication nonadherence using the five WHO model dimensions
of adherence.
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Methods
Design and Sample
The methods used in this study have been described previously and are summarized here.14
This was a prospective study of adults with Stage C chronic HF who were enrolled from
three sites in the Northeastern U.S. One site was a university referral center, one was a
Veterans Affairs Medical Center, and one was a regional medical center. Stage C, presence
of previous or current symptoms of HF in persons with an underlying structural heart
problem but managed with medical treatment, was confirmed based on echocardiographic
and clinical evidence. Potential subjects were screened for visual and hearing adequacy and
English literacy. Otherwise eligible individuals were excluded if they lived in a setting
where medication administration was not an independent activity, if they worked nights or
rotating shifts, or if they had renal failure requiring dialysis, an imminently terminal illness,
plans to move out of the area, or a history of serious drug or alcohol abuse within the past
year. Those with a history of major depressive illness were excluded because depression is
known to influence self-care.15 Although both major and minor depression are associated
with poor self-care,16 we excluded only those with major depression because some of the
symptoms of depression mirror those of HF. Avoiding all symptoms of depression would
have severely limited enrollment. Potential participants were screened with the 9-item
Patient Health Questionnaire (PHQ-9).17 Those reporting 5 or more of the 9 symptoms more
than half the days in the past 2 weeks were excluded if one of the symptoms was depressed
mood or anhedonia.
Institutional Review Board approval was obtained from all three sites and all participants
gave written informed consent. Data were collected at baseline, 3 and 6 months later by
research assistants during home visits. These data were collected between 2007 and 2010.
In total, 280 subjects were enrolled in the study. Attrition from the study was 13.6%; 242
finished the 6-month study and were included in the analytic dataset. Reasons for attrition
included death (n=6), too ill to continue (n=7), withdrawal (n=5), and loss to follow-up
(n=20). For the current study, taking, dosing, timing, and drug holiday components of
medication nonadherence could only be described in the 202 subjects who used the MEMS
device during the 6 months of the study. The 40 subjects who completed the study but did
not use the MEMS device for the full 6-months were more likely to be non-white, to be
taking a drug that needed to be taken more than once daily, to report worse health status, and
to have objectively measured lapses in attention.
Measurement
Adherence to the medication regimen was assessed using MEMS. Unobtrusive
microelectronic monitoring devices in the caps of medication containers document each time
that the cap is removed from a medication vial. Real-time data are collected in the device
and later downloaded to a personal computer and integrated with other data for analysis.
Cross validation studies have shown that electronic monitoring using MEMS is more
sensitive, reliable and valid than other measurement techniques such as pill counts,
biochemical assays, collateral reports, or clinical judgment.18
MEMS data were collected on one medication scheduled to be taken at a fixed time. Others
have shown that patient adherence with medications is generally consistent among drugs in
the regimen when the side-effects of specific medications are accounted for; thus, one
medicine was used to minimize subject burden.19 Our first choice of drugs was an
angiotensin-converting enzyme inhibitor (ACE-I) because ACE-I may be taken more often
in multiple daily doses than other drugs for HF and most patients are prescribed an ACE-I. If
patients were not taking a multiple-dose ACE-I, an angiotensin II receptor blocker (ARB) or
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a β-blocker was monitored. The medicine allocated to the MEMS device was to be taken
twice daily by 57.9% of participants and three times or more daily by 3% of participants;
others were taking their medicines once daily. Participants were fully informed about the
functioning of the MEMS device and instructed on how to use and integrate the device into
their daily routine. For patients who routinely used a pill box to organize their medicines, we
asked them to use the MEMS container in addition to the pillbox. To facilitate this, a note
was placed in the appropriate slot of the pillbox to remind them to take the medicine out of
the MEMS container. MEMS data were collected over the entire 6 month interval and
downloaded at 3 and 6 months. Deviations in use such as accidental openings were noted in
study diaries and used to correct the MEMS data before analysis. There is evidence that use
of the MEMS may influence medication taking behavior initially. That is, patients may take
their medications more consistently at first because they know they are being monitored.20
We took this into consideration by modeling trajectories of nonadherence as a function of
MEMS data in two separate intervals.
The World Health Organization (WHO) dimensions were measured as follows (Table 1).
Social and economic characteristics of race, household income, education, and practical self-
care support were measured by self-report. Formal education is thought to be an inconsistent
indicator of knowledge in the U.S. so education was measured indirectly using oral reading
scores on the revised American National Adult Reading Test (ANART-R).21 Scores range
from 0–50 reflecting the number of irregular words (e.g. bouquet, capon) pronounced
correctly. Practical support for self-care was measured with a 7-item true/false survey
measuring specific ways in which family and friends assist with the treatment regimen (e.g.,
they remind me of things I need to do, they drive me places like the doctor’s office, they
help me interpret my symptoms).
Condition-related influences included comorbid illnesses, depression, EDS, functional class,
physical limitations, symptoms, social limitations, and quality of life. The number of
comorbid illnesses was abstracted at enrollment from the medical record by registered
nurses using the Charlson Index. The total score was used in analysis. Depression was
assessed using the 2-item Patient Health Questionnaire (PHQ-2).17 This short version of the
PHQ-9 was used to avoid items assessing fatigue and sleepiness, which were measured in
other ways. Dichotomized scores on the Epworth Sleepiness Scale was used to measure
EDS.22 To assess functional class, research assistants interviewed patients about activities
causing symptoms using a structured interview.23 Interview results were used by a single
board-certified cardiologist to score New York Heart Association (NYHA) functional class.
Symptoms, physical limitations, social limitations, and quality of life were assessed using
the Kansas City Cardiomyopathy Questionnaire (KCCQ), a 23-item disease-specific
questionnaire.24 Responses are scored on a Likert scale, summed, and standardized to a
scale of 100, with higher scores indicating better health status.
The therapy-related dimensions specific to medication adherence included the total number
of prescription medications taken daily and the prescribed dosing frequency for the
medication used in the MEMS device. To capture the number of routine medications,
research assistants gathered information on every medicine taken during face-to-face visits,
usually by direct review of medication containers.
Patient-related characteristics included gender, health perceptions, knowledge of HF, and
cognitive impairment. Perceived overall health was measured with a single item: How
would you rate your health? (fair, poor, good/very good). To assess HF knowledge, subjects
completed the Dutch HF Knowledge Scale, a 15-item survey with a possible score range of
0 to 15. The scale measures HF knowledge in general, knowledge of HF treatments, and HF
symptom recognition.25 Higher scores indicate more knowledge. We previously
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demonstrated that lapses in attention were the primary cognitive contributor to self-reported
medication nonadherence.14 So, dichotomized scores on the Psychomotor Vigilance Task
(PVT) were used as the measure of cognition; > 4.69 (transformed) lapses was judged as an
abnormally high level of inattention.26
Health care system factors assessed were the participants’ perception that the cost of
medications was a factor impairing medication adherence (yes or no) and the receipt of HF
specialty care (yes or no). Both of these factors were assessed by self-report.
Statistical Analysis
Latent growth mixture modeling (GMM) was used to identify distinct trajectories of
nonadherence. GMM identifies trajectories that vary around different means and have
unique estimates of variances, separate covariate influence, and homogenous within-
trajectory growth. Unlike deterministic methods of clustering that involve minimizing
within-group and maximizing between-group variance, GMM employs a model-based
naturalistic approach wherein probabilities of trajectory membership are calculated. Cases
are then assigned to a “most likely” trajectory and uncertainty in trajectory membership is
quantified. Our GMM included taking (%), timing (%), and dosing adherence (%), and drug
holidays (yes or no) recorded from the MEMS during the first 3 months and the second 3
months of the study. We compared fit among models with 2 to 5 trajectories using Mplus
v6.0 (Los Angeles, CA). The Lo-Mendell-Rubin adjusted likelihood ratio test (p<0.05),27
parametric bootstrapped likelihood ratio test (p<0.05),28 Bayesian Information Criterion
(BIC),29 convergence (entropy near 1.0), the proportion of sample in each trajectory (not
less than 5%), and posterior probabilities (average posterior probability of belonging in
“most likely” trajectory near 1.0) were used to compare alternative models (e.g. k vs. k-1
trajectories) and quantify model uncertainty.30, 31 Changes in adherence by trajectory were
quantified using pairwise t tests, repeated-measures ANOVA, or McNemar’s tests where
appropriate. Out of concern for the potential effects of model saturation, predictors of
unfavorable trajectories of medication adherence were quantified using backward stepwise
logistic regression modeling (p set to 0.20) in StataMP 11 (College Station, TX). Odds ratios
(OR) and 95% confidence intervals (CI)s were calculated for each model factor, and model
fit was quantified using χ2, McFadden’s pseudo R2 and Hosmer-Lemeshow goodness-of-fit
tests.
Results
The characteristics of these 202 subjects at study enrollment are shown in Table 2. The
average subject was 63 years old, male (65.4%), white (68.3%) and had 2.8 comorbid
conditions. Most (54.9%) had government health insurance; only 1 individual was
uninsured. Overall, there were significant—yet heterogeneous increases in taking
nonadherence (81.3%±25.8% vs. 87.2%±19.4%; t = 4.51; p<0.001), dosing nonadherence
(73.2%±30.1% vs. 79.7%±23.8%; t = 4.89; p<0.001), and timing nonadherence (59.0%
±32.8% vs. 65.5%±29.6%; t = 4.99; p<0.001) over time (i.e. comparing data from the
second 3 months with data from the first 3 months of the study). Comparable proportions of
patients took drug holidays during the second 3 months compared with the first 3 months of
the study (47.0% vs. 47.5%; p=0.177).
Using GMM, we identified two distinct trajectories of nonadherence. Both the Lo-Mendell-
Rubin test (781.8; p=0.0007) and parametric bootstrapped likelihood ratio test (811.23;
p<0.001) supported 2 vs. 1 trajectories, model entropy was 0.975, and sample-size adjusted
BIC was 10719.3. Based on observed characteristics, we labeled the first and largest
trajectory (n=157, 77.8%) as a “persistent adherence” subgroup; average posterior
probability for membership in this trajectory was 98.3%. We labeled the second trajectory
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(n=45, 22.3%) as a “steep decline” subgroup; average posterior probability for membership
in this trajectory was 99.6%.
As displayed in Figure 1, those in the persistent adherence subgroup had minimal changes in
taking adherence during the study, whereas those in the steep decline subgroup had
considerable declines in taking adherence during the study (F=80.33; p<0.001). Similar
patterns existed among the two groups with respect to changes in dosing adherence (F=72.9;
p<0.001) and timing adherence (F=58.62; p<0.001). In addition, the frequency of drug
holidays increased slightly for patients in the persistent adherence subgroup (38.9% to
43.9%; p=0.172), and increased moderately in the steep decline subgroup (77.8% to 84.4%;
p<0.001).
Determinants of steep declines in adherence are presented in Table 3 (model χ2 = 24.7;
p=0.0005; pseudo R2 = 13.5%; Hosmer-Lemeshow = 65.32, p=0.636). Based on the WHO
model, three contributors to a steep decline in adherence were identified. Specifically,
participants with lapses in attention, those with excessive daytime sleepiness, and those with
two or more medication dosings per day were more likely to have a steep decline in
adherence over time than to have persistent adherence.
Discussion
To the best of our knowledge, this is the first study to explore patterns of objectively
measured medication adherence using a naturalistic rather than a deterministic approach in
adults with HF. In this study we identified two distinct trajectories: persistent adherence and
a steep decline in medication adherence. Taking, dosing, and timing adherence decreased
significantly over time in the steep decline subgroup and drug holidays were more common.
Three likely contributors to a steep decline in adherence were identified: lapses in attention,
excessive daytime sleepiness, and dosing frequency. These factors represent three of the five
WHO dimensions as predictors of nonadherence. No one dimension was over-represented
suggesting the usefulness of the WHO model is the analysis of this important issue.
The only therapy-related dimension we identified as important in medication nonadherence
was dosing frequency, which has been identified repeatedly as an important factor
influencing medication adherence in chronically ill populations.1 Others have demonstrated
that adherence is better with medications prescribed once versus twice daily.32, 33 A similar
relationship exists for once versus thrice daily 2, 32, 34 and once versus four daily doses.34
Some have suggested that taking a medication two or three times daily is still better in
promoting adherence than four times daily.35 Timing adherence also improves when the
dosing regimen declines.1, 19 These results should serve to remind clinicians of the
importance of streamlining the dosing schedule whenever possible.
Excessive daytime sleepiness contributed to a steep decline in medication adherence over
time, confirming our prior results obtained by self-report in this same sample.14 In that
study, subjects with EDS and cognitive decline were 2.5 times as likely to report being
nonadherent compared with subjects without EDS or cognitive decline. The component of
cognition most associated with nonadherence was lapses in attention, which also confirms
these results.
Finding that lapses in attention contribute to objectively measured nonadherence contributes
to our growing understanding of medication nonadherence. Lim and Dinges argue that the
ability to sustain attention is the fundamental process underlying cognitive processing.36 If
sustained attention is needed for memory, some HF patients may not be able to sustain the
attention needed to establish a consistent pattern of execution and persistence in medication
taking. Wu et al2 noted in their systematic review that forgetfulness was associated with
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nonadherence in all of the studies in which forgetfulness was examined. Together these
results suggest that poor sleep may contribute to inattention, which together pose a
significant risk for nonadherence. Factors other than sleep deprivation known to impair the
ability to be attentive include anxiety, boredom and distraction.37 In this sample, the most
likely contributor to inattention was poor sleep. In a prior analysis we demonstrated that
21.8% of this sample had significant sleep dysfunction.38
Most authors have found medication nonadherence rates between 40–60% in patients with
HF. In our study, taking adherence averaged 81%–87%, dosing adherence averaged 73%–
80%, and timing adherence averaged 59%–66% with considerable heterogeneity. Ours is a
very different perspective on adherence, however, and it is important to recognize that we
are not reporting an overall adherence rate. Instead, it is the proportion of patients who were
categorized as being persistently adherent. The persistent adherers had rates approximately
94% for taking adherence, approximately 89% for dosing adherence, and approximately
74% for timing adherence. As such, we cannot compare this number to other average and
direct calculations of overall adherence. What we can say is that 70.8% of patients fit the
persistent adherence profile which is not the same as saying the medication nonadherence
rate was approximately 29%. We believe that this approach represents a significant advance
in how nonadherence is measured and examined.
Several of the factors anticipated to predict medication adherence were not significant
predictors. Practical support for self-care was not significant in any of the models, although
in the meta-analysis by DiMatteo39 the odds of adherence were 3.6 times higher among
those who received practical support than among those who did not. Neither income nor the
cost of medications was a significant predictor of dosing adherence, contrary to what others
have found.40, 41 Minor depression also was not a significant predictor of adherence,
although we cannot say anything about major depression because those individuals were
excluded from enrollment. The most likely reason for the difference between our results and
those of others is the method of measurement; most prior studies measured adherence using
self-report.
Further research is needed to determine if these results hold in larger samples of HF patients.
If corroborated the two identified groups would likely benefit from very different
interventions. Those with persistent adherence probably need regular encouragement, but no
additional intervention resources. The patients with a steep decline in adherence over time
may be particularly amenable to an intervention focused more on persistence than execution
such as alarms and reminders when medications are due. Screening for patients with lapses
in attention and daytime sleepiness can help identify those patients at risk for declining
adherence. These patients also need a simplified medication dosing regimen. Providers are
strongly encouraged to focus their efforts on simplifying the medication dosing regimen
whenever possible.
Strengths and Limitations
A major strength of this study was the analysis approach, which allowed us to move beyond
mean trends to examine heterogeneity and identify subgroups to explain the heterogeneity.
The major limitation was that a small portion of the final sample failed to use the MEMS
device for the full 6 months, which limited the sample size available to analyze the specific
types of medication nonadherence. Some of these participants may have been those using a
pillbox; perhaps using both a pillbox and the MEMS device was too arduous for them.
However, no data from these subjects were used in the analysis, so this was not judged to be
a major limitation. Sensitivity analyses suggest that these findings might have been even
more robust had all participants used the device because those without 6 months of MEMS
data were subjects with lapses in attention and multiple dosing regimens. Moreover, our
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mean estimates and precision of ORs must be interpreted with an appreciation of the small
subgroup and overall sample sizes. Although we were successful in identifying unique
subgroups of nonadherence and significant predictors thereof, additional testing in a larger
sample would increase the precision of the odds ratio estimates and further limit the risk of
errors of the first and second kind.
In summary, in this study of adults with HF we demonstrated the complexity of medication
adherence and the factors contributing to nonadherence. Clearly, nonadherence is a complex
and multifaceted issue that defies a simple solution. These results, however, illustrate some
potentially modifiable contributors to nonadherence that could be addressed in future
intervention trials.
Acknowledgments
This work was funded by the National Heart, Lung & Blood Institute (RO1 HL084394-01A1) and by the
Philadelphia Veterans Affairs Medical Center, VISN 4 Mental Illness Research, Education, and Clinical Center
(MIREC).
The authors gratefully acknowledge Thomas A. Gillespie, MD, FACC for scoring the New York Heart Association
(NYHA) interviews and Jia-Rong Wu, PhD, RN for her review of a prior version of this manuscript.
References
1. Blegen MA. The winding road from research to practice through theory. Nursing Research. 2011;
60:367. [PubMed: 22067593]
2. Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart
failure: A review of the literature. Nurs Clin North Am. 2008; 43:133–153. vii–viii. [PubMed:
18249229]
3. Esposito D, Bagchi AD, Verdier JM, Bencio DS, Kim MS. Medicaid beneficiaries with congestive
heart failure: Association of medication adherence with healthcare use and costs. The American
journal of managed care. 2009; 15:437–445. [PubMed: 19589011]
4. Fitzgerald AA, Powers JD, Ho PM, Maddox TM, Peterson PN, Allen LA, Masoudi FA, Magid DJ,
Havranek EP. Impact of medication nonadherence on hospitalizations and mortality in heart failure.
Journal of Cardiac Failure. 2011; 17:664–669. [PubMed: 21807328]
5. Wu JR, Moser DK, Chung ML, Lennie TA. Objectively measured, but not self-reported, medication
adherence independently predicts event-free survival in patients with heart failure. J Card Fail.
2008; 14:203–210. [PubMed: 18381183]
6. De Geest S, Sabate E. Adherence to long-term therapies: Evidence for action. European journal of
cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European
Society of Cardiology. 2003; 2:323. [PubMed: 14667488]
7. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive
drug treatments: Longitudinal study of electronically compiled dosing histories. Bmj. 2008;
336:1114–1117. [PubMed: 18480115]
8. World Health Organisation. Overview: Medication adherence–where are we today?; 2006. p. 7-16.
9. Murray MD, Young JM, Morrow DG, Weiner M, Tu W, Hoke SC, Clark DO, Stroupe KT, Wu J,
Deer MM, Bruner-England TE, Sowinski KM, Smith FE, Oldridge NB, Gradus-Pizlo I, Murray LL,
Brater DC, Weinberger M. Methodology of an ongoing, randomized, controlled trial to improve
drug use for elderly patients with chronic heart failure. The American journal of geriatric
pharmacotherapy. 2004; 2:53–65. [PubMed: 15555479]
10. Dahri K, Shalansky SJ, Jang L, Jung L, Ignaszewski AP, Clark C. Accuracy of a provincial
prescription database for assessing medication adherence in heart failure patients. The Annals of
pharmacotherapy. 2008; 42:361–367. [PubMed: 18303147]
11. Gwadry-Sridhar F, Guyatt G, O'Brien B, Arnold JM, Walter S, Vingilis E, MacKeigan L. Teach:
Trial of education and compliance in heart dysfunction chronic disease and heart failure (hf) as an
increasing problem. Contemporary clinical trials. 2008; 29:905–918. [PubMed: 18703166]
Riegel et al. Page 8
Circ Heart Fail. Author manuscript; available in PMC 2013 July 01.
12. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge,
and skills with emergency department visits by adults 50 years or older with congestive heart
failure. Am J Health Syst Pharm. 2004; 61:2043–2049. [PubMed: 15509127]
13. Patterson ME, Blalock SJ, Smith AJ, Murray MD. Associations between prescription copayment
levels and beta-blocker medication adherence in commercially insured heart failure patients 50
years and older. Clinical therapeutics. 2011; 33:608–616. [PubMed: 21665045]
14. Riegel B, Moelter ST, Ratcliffe SJ, Pressler SJ, De Geest S, Potashnik S, Fleck D, Sha D, Sayers
SL, Weintraub WS, Weaver TE, Goldberg LR. Excessive daytime sleepiness is associated with
poor medication adherence in adults with heart failure. J Card Fail. 2011; 17:340–348. [PubMed:
21440873]
15. Gonzalez JS, Safren SA, Delahanty LM, Cagliero E, Wexler DJ, Meigs JB, Grant RW. Symptoms
of depression prospectively predict poorer self-care in patients with type 2 diabetes. Diabetic
medicine : a journal of the British Diabetic Association. 2008; 25:1102–1107. [PubMed:
19183315]
16. Egede LE, Ellis C, Grubaugh AL. The effect of depression on self-care behaviors and quality of
care in a national sample of adults with diabetes. General hospital psychiatry. 2009; 31:422–427.
[PubMed: 19703635]
17. Kroenke K, Spitzer RL, Williams JB. The phq-9: Validity of a brief depression severity measure.
Journal of General Internal Medicine. 2001; 16:606–613. [PubMed: 11556941]
18. Knafl GJ, Fennie KP, Bova C, Dieckhaus K, Williams AB. Electronic monitoring device event
modelling on an individual-subject basis using adaptive poisson regression. Stat Med. 2004;
23:783–801. [PubMed: 14981675]
19. Viswanathan H, Anderson R, Thomas J 3rd. Evaluation of an antiretroviral medication attitude
scale and relationships between medication attitudes and medication nonadherence. AIDS Patient
Care STDS. 2005; 19:306–316. [PubMed: 15916493]
20. Deschamps AE, Van Wijngaerden E, Denhaerynck K, De Geest S, Vandamme AM. Use of
electronic monitoring induces a 40-day intervention effect in hiv patients. J Acquir Immune Defic
Syndr. 2006; 43:247–248. [PubMed: 17003672]
21. Gladsjo JA, Heaton RK, Palmer BW, Taylor MJ, Jeste DV. Use of oral reading to estimate
premorbid intellectual and neuropsychological functioning. Journal of the International
Neuropsychological Society : JINS. 1999; 5:247–254. [PubMed: 10217924]
22. Johns MW. Reliability and factor analysis of the epworth sleepiness scale. Sleep. 1992; 15:376–
381. [PubMed: 1519015]
23. Kubo S, Schulman S, Starling R, Jessup M, Wentworth D, Burkhoff D. Development and
validation of a patient questionnaire to determine new york heart association classification. J Card
Fail. 2004; 10:228–235. [PubMed: 15190533]
24. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the kansas city
cardiomyopathy questionnaire: A new health status measure for heart failure. Journal of the
American College of Cardiology. 2000; 35:1245–1255. [PubMed: 10758967]
25. van der Wal MH, Jaarsma T, Moser DK, van Veldhuisen DJ. Development and testing of the dutch
heart failure knowledge scale. Eur J Cardiovasc Nurs. 2005; 4:273–277. [PubMed: 16126459]
26. Dinges DF, Pack F, Williams K, Gillen KA, Powell JW, Ott GE, Aptowicz C, Pack AI.
Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements
during a week of sleep restricted to 4–5 hours per night. Sleep. 1997; 20:267–277. [PubMed:
9231952]
27. Lo Y, Mendell NR, Rubin DB. Testing the number of components in a normal mixture.
Biometrika. 2001; 88:767–778.
28. Ram N, Grimm KJ. Methods and measures: Growth mixture modeling: A method for identifying
differences in longitudinal change among unobserved groups. International Journal of Behavioral
Development. 2009; 33:565–576.
29. Schwarz GE. Estimating the dimension of a model. Annals of Statistics. 1978; 6:461–464.
30. Jung T, Wickrama KA. An introduction to latent class growth analysis and growth mixture
modeling. Social and Personality Compass. 2008; 2:302–317.
Riegel et al. Page 9
Circ Heart Fail. Author manuscript; available in PMC 2013 July 01.
31. Nylund KL, Asparouhov T, Muthen B. Deciding on the number of classes in latent class analysis
and growth mixture modeling: A monte carlo simulation study. Struct Equ Modeling. 2007;
14:535–569.
32. Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A. Electronic pill-boxes in the
evaluation of antihypertensive treatment compliance: Comparison of once daily versus twice daily
regimen. American journal of hypertension. 2000; 13:184–190. [PubMed: 10701819]
33. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens
in respiratory tract infections: Results of a randomized trial. J Antimicrob Chemother. 2007;
59:531–536. [PubMed: 17289766]
34. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens
and medication compliance. Clin Ther. 2001; 23:1296–1310. [PubMed: 11558866]
35. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as
prescribed? A novel assessment technique. JAMA : the journal of the American Medical
Association. 1989; 261:3273–3277. [PubMed: 2716163]
36. Lim J, Dinges DF. Sleep deprivation and vigilant attention. Ann N Y Acad Sci. 2008; 1129:305–
322. [PubMed: 18591490]
37. Cheyne JA, Carriere JS, Smilek D. Absent-mindedness: Lapses of conscious awareness and
everyday cognitive failures. Conscious Cogn. 2006; 15:578–592. [PubMed: 16427318]
38. Riegel B, Glaser D, Richards K, Sayers SL, Marzolf A, Weintraub WS, Goldberg LR. Modifiable
factors associated with sleep dysfunction in adults with heart failure. European journal of
cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European
Society of Cardiology. 2011 Feb 23. [Epub ahead of print].
39. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative
review of 50 years of research. Med Care. 2004; 42:200–209. [PubMed: 15076819]
40. Rockwell JM, Riegel B. Predictors of self-care in persons with heart failure. Heart Lung. 2001;
30:18–25. [PubMed: 11174364]
41. Jackson JE, Doescher MP, Saver BG, Fishman P. Prescription drug coverage, health, and
medication acquisition among seniors with one or more chronic conditions. Medical Care. 2004;
42:1056–1065. [PubMed: 15586832]
Riegel et al. Page 10
Circ Heart Fail. Author manuscript; available in PMC 2013 July 01.
Commentary
As many as 60% of heart failure (HF) patients are nonadherent in taking their
medications. Hospitalizations, costs, and death are higher in HF patients who do not take
their medications as prescribed. In this study we followed 202 adults with HF for 6
months, measuring their daily medication adherence electronically. Latent growth
mixture modeling was used to identify patterns of adherence. The World Health
Organization (WHO) dimensions of adherence (socioeconomic, condition, therapy,
patient, and health care system) were tested to identify contributors to nonadherence. We
identified two distinct groups of patients: those (77.8%) who were persistently adherent
in their medicines as prescribed and a subset (22.3%) who had a steep decline over time
in adherence. Three contributors to the steep decline in adherence were identified: lapses
in attention, excessive daytime sleepiness, and those taking a medication two or more
times per day. Medications that need to be taken in multiple daily doses are known to be
associated with poor adherence, but this study confirms the importance of prescribing
once a day medicines whenever possible. Excessive daytime sleepiness and lapses in
attention are likely correlated, in that patients who do not sleep well are more sleepy
during the day and may have trouble being sufficiently vigilant or attentive to remember
to take their medicines. Thus, promoting sleep may be a modifiable factor that could
improve medication adherence.
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Figure 1.
Three Trajectories of Medication Adherence
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Table 1
Factors tested as potential contributors to medication nonadherence.
      1. Social and Economic Dimension       3. Therapy-Related Dimension
Education Number of medications taken per day
Race Dosing frequency of medicine used in the MEMS device
Household income
      4. Patient-Related Dimension
Practical support for self-care Gender
      2. Condition-Related Dimension Perceived Overall Health
Comorbid illnesses Knowledge of heart failure
Depression Cognition and attentiveness
Excessive daytime sleepiness
      5. Health Care System Dimension
NYHA functional class Cost of medications
KCCQ Physical limitations Receipt of heart failure specialty services
KCCQ symptom frequency, burden, stability
KCCQ social limitations
KCCQ quality of life
NYHA = New York Heart Association; KCCQ = Kansas City Cardiomyopathy Questionnaire; MEMS = medication electronic monitoring system.
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Table 2
Characteristics of the sample. Mean ± standard deviation or column n (%) are reported.
(n=202)
Age (years) 63.1±11.8
Male 132 (65.4)
Race/Ethnicity
• White 138 (68.3)
• Non-White 64 (31.7)
Education
• Less than high school 17 (8.4)
• High school 68 (33.7)
• Some college 117 (57.9)
ANART-R score 30.9±11.2
Household income
• More than enough 78 (38.6)
• Enough 92 (45.5)
• Not enough 32 (15.8)
Perceived overall health
• Good, very good 103 (51.0)
• Fair 78 (38.6)
• Poor 21 (10.0)
Total number of comorbid conditions on Charlson Index 2.8±1.8
NYHA functional class
• Class I & II 49 (24.3)
• Class III 119 (58.9)
• Class IV 34 (16.8)
Daily Dosing with MEMS
1; once daily 79 (39.1)
2; twice daily 117 (57.9)
3; thrice or more daily 6 (3.0)
# of daily medications 9.9±3.8
High lapses on the PVT 71 (35.9)
Excessive Daytime Sleepiness (≥6) 112 (55.5)
Patient Health Questionnaire (PHQ2) 0.8±1.0
Self-Care Support Score 1.5±1.5
Medication costs impair adherence 20 (10.3)
KCCQ Physical Limit Score 71.6±22.0
KCCQ Symptom Score 76.3±19.4
KCCQ Social Limitations Score 68.4±25.3
KCCQ Quality of Life Score 66.7±23.3
Dutch Knowledge Scale Score 11.7±1.7
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MEMS= Medication Event Monitoring System; ANART-R = revised American National Adult Reading Test; NYHA = New York Heart
Association; KCCQ = Kansas City Cardiomyopathy Questionnaire; PHQ2 = 2-items Patient Health Questionnaire; PVT = psychomotor vigilance
task.
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Table 3
Logistic regression model predicting steep declines in adherence using MEMS data.
Steep Declines in Adherence
Variable Grouped by Dimension OR (95% CI), p-value
Social & economic dimension
Caucasian (vs. Non-Caucasian) 0.55 (0.23–1.28), 0.162
Condition-related dimension
Depression 0.73 (0.48–1.12), 0.151
Excessive daytime sleepiness 2.51 (1.06–5.95), 0.037
Therapy-related dimension
2+ medication dosings per day 2.59 (1.19–5.64), 0.016
Patient-related dimension
Lapses in attention on PVT 2.65 (1.14–6.16), 0.023
Health care system dimension
Heart failure specialty services 1.77 (0.78–4.02), 0.173
Note: Adjusted odds risk ratios are displayed with persistent adherence as the referent subgroup. CI = Confidence Interval; HF = Heart failure;
MEMS= Medication Event Monitoring System; OR = odds ratio; PVT = psychomotor vigilance task.
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